Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will speak at two virtual investor conferences on September 17, 2020. The events are the Morgan Stanley 18th Annual Global Healthcare Conference at 8:45 a.m. ET and the Cantor Fitzgerald Virtual Global Healthcare Conference at 10:00 a.m. ET. Both presentations will be webcast live on Zentalis' website. The company focuses on developing small molecule therapeutics targeting cancer pathways, with a promising pipeline including ZN-c5 for breast cancer and other inhibitors.

NEW YORK and SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.

Presentation Details:

Event: Morgan Stanley 18^th Annual Global Healthcare Conference
Date: Thursday, September 17, 2020
Time: 8:45 a.m. ET

Event: Cantor Fitzgerald Virtual Global Healthcare Conference
Date: Thursday, September 17, 2020
Time: 10:00 a.m. ET

Live webcasts from the Morgan Stanley and Cantor fireside chats will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website.

About Zentalis  

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including  ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Investor Contact:
Thomas Hoffmann
Solebury Trout
1.646.378.2931
thoffmann@soleburytrout.com

Media Contact:
Julia Deutsch
Solebury Trout
1.646.378.2967
jdeutsch@soleburytrout.com

FAQ

What is Zentalis Pharmaceuticals' participation in investor conferences?

Zentalis Pharmaceuticals will have CEO Anthony Sun participate in two virtual investor conferences on September 17, 2020.

When will Zentalis present at the Morgan Stanley Healthcare Conference?

Zentalis will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020, at 8:45 a.m. ET.

What time is the Cantor Fitzgerald Virtual Global Healthcare Conference for Zentalis?

The Cantor Fitzgerald Virtual Global Healthcare Conference is scheduled for September 17, 2020, at 10:00 a.m. ET.

Where can I watch Zentalis' investor conference presentations?

The presentations will be webcast live on the Investors section of Zentalis' website.

What are the key products in Zentalis' pipeline?

Zentalis is developing products like ZN-c5, a selective estrogen receptor degrader for breast cancer, and other inhibitors targeting WEE1, BCL-2, and EGFR.